PROTEINA
29.4.2024 06:18:35 CEST | Business Wire | Press release
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.”
PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be soon published in a high-profile scientific journal, Nature Biomedical Engineering, later this year.
Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory. Dr. Janghee Woo, a hematologist at Emory, has spearheaded a translational research laboratory focused on deciphering the molecular mechanisms underlying hematological malignancies to improve clinical outcomes. This endeavor entails the collection and examination of several hundred AML samples to investigate the molecular intricacies of the disease and pinpoint biomarkers linked to therapeutic response. PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
Dr. Janghee Woo expressed optimism, stating, “This project will not only validate the clinical efficacy of the PPI PathFinder but also allow for collaboration across various fields through the expansion of solutions to further indications of Venetoclax.”
PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States. We are committed to diligently completing the validation process as this would represent the first step towards wide use of PROTEINA SPID platform in providing PPI biomarkers for the emerging class of PPI-modulating drugs.”
Furthermore, through this project, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform and plans to supply the solution to overseas CLIA-certified labs based on the results of this exploratory clinical study.
About PROTEINA
Founded in 2015 in Seoul, PROTEINA is a leader in proteomics, enhancing drug research with its innovative Single-molecule Protein Interaction Detection (SPID) technology. This platform provides exceptional sensitivity for detecting protein-protein interactions, essential for pharmaceutical R&D. Serving top pharmaceutical companies and academic institutions worldwide, PROTEINA’s technology advances understanding of human biology, supporting modern healthcare solutions. With collaborations across Europe and North America, PROTEINA delivers insights that propel drug development and proteomic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428101218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kyrgyzstan’s National Interbank Processing Center Partners With Alipay+ to Launch International QR Payments4.6.2026 04:00:00 CEST | Press release
With the support of the National Bank of Kyrgyz Republic, Interbank Processing Center (IPC), Kyrgyzstan’s national payment system operator, and Alipay+, Ant International’s unified wallet gateway, have launched international QR payments for users of the ELCARD Mobile app. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603760762/en/ (L-R) Altymysh Turatbekov, Chairman of the National Interbank Processing Center; Pan Yan, Head of Strategic Partnership for Alipay+, Ant International The launch was officiated by the Chairman of the National Bank of the Kyrgyz Republic. Almaz Baketaev, Chairman of the National Bank of the Kyrgyz Republic, said: “Our colleagues from IPC together with Alipay+ launched this project last year, and today we are bringing it into practice. Our citizens now have access to a payment system covering merchants worldwide. Wherever they are, they can make payments in any currency easily and without any com
Murata Introduces World’s First 2.2μF/100Vdc Soft-Termination Chip MLCC in 0805-inch Size for Automotive Applications4.6.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) introduces the GCJ21BD72A225KE02, a soft-termination chip multilayer ceramic capacitor (MLCC) for automotive powertrain and safety equipment. This world's first soft-termination chip MLCC product achieves the highest available capacitance of 2.2μF at 100Vdc in the smallest 0805-inch (2.0×1.25mm) size*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603192945/en/ [Murata Manufacturing Co., Ltd.] 2.2µF/100Vdc Soft-Termination Chip MLCC in 0805-inch Size for Automotive Applications As vehicle electrification accelerates and autonomous driving (AD) and advanced driver-assistance systems (ADAS) grow more sophisticated, engineers face increasing pressure to pack more functionality into tighter board spaces. The wider adoption of 48V power systems further demands components that combine high capacitance, high voltage tolerance, and a small footprint. At the same t
Megaport Launches Storage, Unifying Its Automated Infrastructure Platform Alongside Compute and Network Offerings4.6.2026 00:47:00 CEST | Press release
Megaport Storage enables enterprises to run data-intensive workloads on dedicated software-defined infrastructure with cloud-like agility and predictable costs. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport Storage, expanding its platform to deliver integrated compute, network, and storage services. Megaport Storage integrates high-performance, enterprise cloud storage directly into the Megaport Network and Latitude.sh compute platform, giving enterprises a unified foundation that covers the three key pillars of IT infrastructure: compute, network, and storage. The launch marks a culminating step in Megaport’s evolution, delivering predictable costs, seamless scalability, and direct data access wherever customers operate. “With the launch of Megaport Storage, we’re not just connecting your cloud anymore; we’re providing the foundation for it,” said Michael Reid, CEO of Megaport. “By aligning storage
C.H. Robinson Launches World's First AI Technology That Continually Assesses, Improves and Operates Global Supply Chains3.6.2026 18:00:00 CEST | Press release
The newest innovation for Managed Solutions, the Lean AI Engineer, is the brain of the system As the global leader in Lean AI supply chains, C.H. Robinson has built the first AI technology designed to both operate a shipper’s global supply chain and also continuously assess and improve its performance. Now serving the company’s 4PL Managed Solutions customers, a new Lean AI Engineer works in concert with the Lean AI Planner introduced last year to create one connected system that uniquely enhances a supply chain as it runs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520874794/en/ The Lean AI Engineer can assess an entire supply chain in 25 to 30 minutes and determine improvements before performance is impacted – compared to supply chain assessments that typically take up to four weeks and look backward at what has happened instead of what should happen. While the Lean AI Engineer delivers intel, the Lean AI Planner ma
Leading Global Brain Science Conference OHBM 2028 to Be Held in Yokohama3.6.2026 17:00:00 CEST | Press release
Yokohama has won the bid to host the 2028 Annual Meeting of the Organization for Human Brain Mapping (OHBM 2028), one of the world’s premier international conferences in brain science, further elevating the city’s presence as a global hub for international conventions and academic exchange. The meeting will take place at PACIFICO Yokohama from June 18–22 and will mark only the second time the meeting has been held in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603787692/en/ YOKOHAMA JAPAN'S FIRST PORT OF CALL OHBM is a leading international academic society in the fields of brain imaging, neuroscience, and neurological-disease research. Its annual meeting attracts around 3,000 researchers, healthcare professionals, and industry representatives from around the world. OHBM 2028 will be organized in collaboration with the Japan Human Brain Mapping Society (JHBM, President: Yoshikazu Ugawa and Tetsuya Matsuda). The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom